HAE Acute Treatment from Takeda.
Firazyr is a bradykinin B2 receptor antagonist for acute treatment of HAE attacks. Its subcutaneous route makes it convenient for patient self-administration at home or while traveling, allowing early treatment of attacks.
Firazyr is FDA-approved for the following indications:
Firazyr is administered as a subcutaneous self-injection at attack onset. Patients are prescribed multiple doses for home stocking and trained on technique.
The manufacturer offers a patient support program — Takeda OnePath — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.takedapatientsupport.com.
Treatment with Firazyr is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. This is a subcutaneous self-administered medication. After prior authorization, the prescription is sent to a specialty pharmacy that ships the medication directly to the patient. A manufacturer-sponsored nurse or office-based training visit is typically arranged for the first dose so patients are confident with self-administration before continuing at home.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.firazyr.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Firazyr is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.